Mthera Pharma

Focus: Mthera Pharma is a Korea-based pharmaceutical company specializing in botanicals and live therapeutics across neurology, cardiovascular, oncology, and women's health. The company derives 97% of revenue from XPOVIO (selinexor), a peak-stage nuclear export inhibitor.

Neurology Cardiovascular Oncology Women's Health

Profile data last refreshed 10m ago · AI intelligence enriched 1w ago

Open Jobs

About Mthera Pharma

AI assessmentNot Hiring

No open roles listed right now. Follow Mthera Pharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

1 in 5yr

OLEPTRO

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

XPOVIO

Multiple (NDA approved)

$86M

Peak9.0yr

Dominant revenue driver representing 97% of company sales; nuclear export inhibitor with patent protection through 2035.

Help build intelligence for Mthera Pharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Strong revenue base from XPOVIO ($86M Part D spending) provides stable funding for R&D through 2035 LOE
Emerging pipeline in neurology (MT101-5 for Parkinson's Disease in Phase 1/2) signals growth ambitions beyond single-product dependency
Innovative focus on live therapeutics and botanicals represents differentiation in crowded pharma landscape

Watch Out For

Extreme revenue concentration (97% from one drug) creates vulnerability if XPOVIO faces competitive pressure or safety issues
Zero active job openings and minimal hiring data suggest constrained headcount and limited near-term career mobility
Early-stage pipeline (only 2 total programs, no Phase 3 trials) indicates limited near-term catalyst visibility and commercial upside

Generated by Claude from Mthera Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

DANAZOL

Endometriosis, hereditary angioedema

$2M

Pre-Launch

ANDA generic with minimal Part D spending; pituitary-ovarian axis suppressor in pre-launch stage.

THIOTHIXENE

Not specified

Pre-Launch

ANDA generic antipsychotic in pre-launch development with no disclosed revenue.

ALBUTEROL SULFATE

Exercise-induced bronchospasm

Pre-Launch

ANDA generic beta-agonist for respiratory use in pre-launch stage.

CLORAZEPATE DIPOTASSIUM

Anxiety disorders

Pre-Launch

ANDA benzodiazepine generic for anxiety in pre-launch development.

TRAZODONE HYDROCHLORIDE

Major depressive disorder

Post-LOE

Post-LOE SSRI/5HT2 antagonist generic with no disclosed revenue.

PRAZOSIN HYDROCHLORIDE

Hypertension

Pre-Launch

ANDA alpha-blocker generic in pre-launch development.

PRAZOSIN HYDROCHLORIDE

Hypertension

Post-LOE

Post-LOE formulation of alpha-blocker with no disclosed revenue.

PREDNISONE

Multiple indications

Pre-Launch

ANDA corticosteroid generic in pre-launch development.

OXAZEPAM

Anxiety disorders

Pre-Launch

ANDA benzodiazepine generic for anxiety in pre-launch stage.

Products & Portfolio (4)

70 discontinued, 12 duplicate formulations not shown

Key Products by Revenue

Nuclear Export Inhibitors

2019

$86M Part D

LOE: 2035

Other Products (3)

Androgen Receptor Agonists

2005

PRAZOSIN HYDROCHLORIDE

Pipeline & Clinical Trials

MT101-5

Parkinson's Disease

Phase 1

Clinical Trials (1)

NCT05844787A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Profile of MT101-5 in Healthy Volunteers

Phase 1

MT101-5

Parkinson's Disease

Phase 2

Clinical Trials (1)

NCT06175767A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects with Early Parkinson's Disease

Phase 2

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 86 approved products, 2 clinical trials

Top TAs: Cardiovascular, Neurology, Immunology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Portfolio Health

Pre-Launch54 (63%)

Peak1 (1%)

LOE Approaching1 (1%)

Post-LOE30 (35%)

86 total products

Therapeutic Area Focus

Cardiovascular

18 marketed

Neurology

14 marketed2 pipeline

Immunology

5 marketed

Psychiatry

4 marketed

Women's Health

3 marketed

prazosin hydrochloride

CLINICAL PHARMACOLOGY The exact mechanism of the hypotensive action of prazosin is unknown. Prazosin causes a decrease in total peripheral resistance and was originally thought to have a direct relaxant action on vascular smooth muscle. Recent animal studies, however, have suggested that the vasodilator effect of prazosin is also related to blockade of postsynaptic alpha-adrenoceptors. The results of dog forelimb experiments demonstrate that the peripheral vasodilator effect of prazosin is confined mainly to the level of the resistance vessels (arterioles). Unlike conventional alpha-blockers, the antihypertensive action of prazosin is usually not accompanied by a reflex tachycardia. Tolerance has not been observed to develop in long term therapy. Hemodynamic studies have been carried out in man following acute single dose administration and during the course of long term maintenance therapy. The results confirm that the therapeutic effect is a fall in blood pressure unaccompanied by a clinically significant change in cardiac output, heart rate, renal blood flow and glomerular filtration rate. There is no measurable negative chronotropic effect. In clinical studies to date, prazosin hydrochloride has not increased plasma renin activity. In man, blood pressure is lowered in both the supine and standing positions. This effect is most pronounced on the diastolic blood pressure. Following oral administration, human plasma concentrations reach a peak at about three hours with a plasma half-life of two to three hours. The drug is highly bound to plasma protein. Bioavailability studies have demonstrated that the total absorption relative to the drug in a 20% alcoholic solution is 90%, resulting in peak levels approximately 65% of that of the drug in solution. Animal studies indicate that prazosin hydrochloride is extensively metabolized, primarily by demethylation and conjugation, and excreted mainly via bile and feces. Less extensive human studies suggest similar metabolism and excretion in man. In clinical studies in which lipid profiles were followed, there were generally no adverse changes noted between pre-and post-treatment lipid levels.

Endocrinology

2 marketed